Current Cardiology Reports

, Volume 10, Issue 4, pp 319–326

Sorting through new biomarkers

Article

DOI: 10.1007/s11886-008-0051-z

Cite this article as:
Wood, F.O. & de Lemos, J.A. Curr Cardiol Rep (2008) 10: 319. doi:10.1007/s11886-008-0051-z

Abstract

Early diagnosis of acute coronary syndromes (ACS) allows for efficient risk stratification, appropriate targeted therapies, and faster patient disposition within crowded emergency departments. Although only troponin testing is recommended for routine use in the 2007 American College of Cardiology/American Heart Association guidelines for non-ST-elevation ACS, emerging data support selected use of other biomarkers, including B-type natriuretic peptides (BNPs) and C-reactive protein. There remains a need to identify additional biomarkers in ACS to enhance risk stratification and to help guide therapeutic decisions in this increasingly complex area of cardiovascular medicine. Cardiac biomarkers may help to diagnosis ACS before cardiomyocyte necrosis, to influence the decision for early invasive treatment, and to provide a means of monitoring response to therapy. In this review, we assess new data in ACS with respect to troponins, BNPs, myeloperoxidase, fatty acid-binding protein, and monocyte chemoattractant protein-1. We also discuss novel biomarkers including growth deficient factor-15 and neopterin.

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Cardiovascular Division and Department of Internal MedicineUT Southwestern Medical CenterDallasUSA

Personalised recommendations